Autor: "Iacovelli R" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Autorzy:: Stellato M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Buti S; Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Maruzzo M; Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padua, Italy.
Bersanelli M; Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Pierantoni F; Medical Oncology Unit 3, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padua, Italy.
De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy.
Di Napoli M; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
Iacovelli R; Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS Roma, 00168 Roma, Italy.
Vitale MG; Medical Oncology, University Hospital Modena, 41121 Modena, Italy.
Ermacora P; Department of Oncology, University and General Hospital, 33100 Udine, Italy.
Malgeri A; Department of Medical Oncology, Fondazione Policlinico Campus Bio-Medico, 00128 Roma, Italy.
Maiorano BA; Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, 73013 San Giovanni Rotondo, Italy.
Prati V; Department of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno-Azienda Sanitaria Locale CN2, Alba-Bra, 12060 Cuneo, Italy.
Mennitto A; SCDU Oncologia, 'Maggiore della Carità' University Hospital, 28100 Novara, Italy.
Cavo A; SSD Oncologia Ospedale Villa Scassi, ASL 3 Genovese, 16149 Genova, Italy.
Santoni M; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Carella C; SSD Oncologia Medica, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.
Fratino L; Division of Medical Oncology C, Centro di Riferimento Oncologico National Cancer Institute, 33081 Aviano, Italy.
Procopio G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Verzoni E; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Santini D; UOC of Medical Oncology, Sapienza Università di Roma, Polo Pontino, 00196 Latina, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Jan 06; Vol. 24 (2). Date of Electronic Publication: 2023 Jan 06.
Typ publikacji:: Observational Study; Journal Article
MeSH Terms:: Carcinoma, Renal Cell*/drug therapy
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Humans ; Axitinib/adverse effects ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Autorzy:: Facchini G; Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via M. Semmola, 80131, Napoli, Italy. .
Rossetti S; Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via M. Semmola, 80131, Napoli, Italy.
Berretta M; Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori CRO, Aviano, PN, Italy.
Cavaliere C; UOC of Medical Oncology ASL NA 3 SUD Ospedali Riuniti Area Nolana, Naples, Italy.
Scagliarini S; Division of Oncology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Naples, Italy.
Vitale MG; Division of Medical Oncology, Azienda Ospedaliera Universitaria Policlinico di Modena, Modena, Italy.
Ciccarese C; Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.
Di Lorenzo G; Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, Naples, Italy.
Palesandro E; Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
Conteduca V; Department of Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy.
Basso U; Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Naglieri E; Division of Medical Oncology, Istituto Oncologico Giovanni Paolo II, Bari, Italy.
Farnesi A; University Hospital of Pisa, Oncology Unit 2, Pisa, Pisa, Italy.
Aieta M; Medical Oncology Department, National Institute of Cancer, Rionero in Vulture, Italy.
Borsellino N; Medical Oncology Unit, 'Buccheri-La Ferla' Hospital, Palermo, Italy.
La Torre L; Medical Oncology Department, 'Santa Maria della Scaletta' Hospital AUSL, Imola, Italy.
Iovane G; Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via M. Semmola, 80131, Napoli, Italy.
Bonomi L; Oncology Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Gasparro D; Civil Hospital, Parma, Italy.
Ricevuto E; S. Salvatore Hospital, ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy.
De Tursi M; Oncology and Experimental Medicine, 'G. D'Annunzio' University, Chieti, Italy.
De Vivo R; Ospedale San Bortolo di Vicenza, Vincenza, Italy.
Lo Re G; NCI Aviano, Oncology Pordenone-S.Vito, Pordenone, Italy.
Grillone F; Medical Oncology Unit Azienda Ospedaliera 'Mater Domini', Catanzaro, Italy.
Marchetti P; Ospedale Sant' Andrea Oncology, Roma, Italy.
De Vita F; Division of Medical Oncology, University of Campania 'L. Vanvitelli', Napoli, Italy.
Scavelli C; Medical Oncology Unit, 'S. Cuore di Gesù' Hospital, Gallipoli, Italy.
Sini C; Oncologia Medica ASL 2, Olbia, Italy.
Pisconti S; Medical Oncology Unit, POC SS Annunziata, Taranto, Italy.
Crispo A; Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via M. Semmola, 80131, Napoli, Italy.
Gebbia V; Medical Oncology Unit, La Maddalena Clinic for Cancer, University of Palermo, Palermo, Italy.
Maestri A; Medical Oncology Department, 'Santa Maria della Scaletta' Hospital AUSL, Imola, Italy.
Galli L; University Hospital of Pisa, Oncology Unit 2, Pisa, Pisa, Italy.
De Giorgi U; Department of Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy.
Iacovelli R; Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.
Buonerba C; Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, Naples, Italy.
Cartenì G; Division of Oncology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Naples, Italy.
D'Aniello C; Division of Medical Oncology, AORN Dei Colli 'Ospedali Monaldi-Cotugno-CTO', Napoli, Italy.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2019 Aug 29; Vol. 17 (1), pp. 296. Date of Electronic Publication: 2019 Aug 29.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Axitinib/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Carcinoma, Renal Cell/*pathology
Kidney Neoplasms/*drug therapy
Kidney Neoplasms/*pathology
Sunitinib/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Axitinib/adverse effects ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
Autorzy:: Pantano F; Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Santoni M; Department of Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle Marche, Piazza Roma, 22,60121 Ancona, Italy.
Procopio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy.
Rizzo M; Department of Medical Oncology, Cardarelli Hospital, Via A. Cardarelli 9, 80131, Naples, Italy.
Iacovelli R; Department of Oncology, Oncology Unit B, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185 Rome, Italy.
Porta C; Department of Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Viale Camillo Golgi, 19, 27100 Pavia, Italy.
Conti A; Department of Clinical and Specialist Sciences, Urology, Università Politecnica delle Marche, Piazza Roma, 22, 60121, Ancona, Italy.
Lugini A; Department of Medical Oncology, San Camillo De Lellis Hospital, Via John Fitzgerald Kennedy, 17, 02100 Rieti, Italy.
Milella M; Department of Medical Oncology, Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00128 Rome, Italy.
Galli L; Department of Medical Oncology, Azienda Ospedaliera Universitaria Pisana, Via Roma, 67, 56126 Pisa, Italy.
Ortega C; Department of Medical Oncology, Institute for Cancer Research & Treatment (IRCC), Strada Provinciale, 142, 10060 Candiolo, Torino, Italy.
Guida FM; Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Silletta M; Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Schinzari G; Department of Medical Oncology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Rome, Italy.
Verzoni E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy.
Modica D; Department of Oncology, Oncology Unit B, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185 Rome, Italy.
Crucitti P; Department of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Rauco A; Department of Medical Oncology, San Camillo De Lellis Hospital, Via John Fitzgerald Kennedy, 17, 02100 Rieti, Italy.
Felici A; Department of Medical Oncology, Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00128 Rome, Italy.
Ballatore V; Department of Medical Oncology, Institute for Cancer Research & Treatment (IRCC), Strada Provinciale, 142, 10060 Candiolo, Torino, Italy.
Cascinu S; Department of Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle Marche, Piazza Roma, 22,60121 Ancona, Italy.
Tonini G; Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Carteni G; Department of Medical Oncology, Cardarelli Hospital, Via A. Cardarelli 9, 80131, Naples, Italy.
Russo A; Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Santini D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Apr 17; Vol. 10 (4), pp. e0120427. Date of Electronic Publication: 2015 Apr 17 (Print Publication: 2015).
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Everolimus/*therapeutic use
Kidney Neoplasms/*drug therapy
Lipid Metabolism/*physiology
Adolescent ; Adult ; Biomarkers/metabolism ; Blood Glucose/analysis ; Blood Pressure ; Body Mass Index ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Cholesterol/blood ; Disease Progression ; Humans ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Neoplasm Staging ; Retrospective Studies ; Survival Rate ; Triglycerides/blood ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma.
Autorzy:: Saroufim A; 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Messai Y; INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Hasmim M; INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Rioux N; Department of Pathology, Pontchaillou Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France.
Iacovelli R; Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Verhoest G; Department of Pathology, Pontchaillou Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France.
Bensalah K; Department of Pathology, Pontchaillou Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France.
Patard JJ; 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Urologic Department, Kremlin-Bicêtre Hospital, 78 rue de General Leclerc, 94275 Le Kremlin Bicêtre, France.
Albiges L; 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Azzarone B; Department of Immunology, Istituto Giannina Gaslini, 16100 Genova, Italy.
Escudier B; 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Chouaib S; INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.; Pokaż więcej
Źródło:: British journal of cancer [Br J Cancer] 2014 Apr 02; Vol. 110 (7), pp. 1778-84. Date of Electronic Publication: 2014 Mar 04.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antigens, CD/*physiology
Biomarkers, Tumor/*physiology
Carcinoma, Renal Cell/*diagnosis
Kidney Neoplasms/*diagnosis
Receptors, Cell Surface/*physiology
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/surgery ; Endoglin ; Female ; Humans ; Kidney Neoplasms/mortality ; Kidney Neoplasms/surgery ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Analysis ; Treatment Outcome ; Young Adult